company background image

OPKO Health NasdaqGS:OPK Stock Report

Last Price


Market Cap







26 Jun, 2022


Company Financials +
OPK fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health5/6

OPK Stock Overview

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally.

OPKO Health Competitors

Price History & Performance

Summary of all time highs, changes and price drops for OPKO Health
Historical stock prices
Current Share PriceUS$2.64
52 Week HighUS$5.25
52 Week LowUS$2.18
1 Month Change-17.50%
3 Month Change-26.26%
1 Year Change-31.61%
3 Year Change8.20%
5 Year Change-59.88%
Change since IPO-41.33%

Recent News & Updates

Jun 21

OPKO Health: 14%+ Short Interest Means More Volatility Over The Near Term

Company misses earnings and sales targets in Q1. New deals abound but the market goes unnoticed. High costs and declining margins continue to put pressure on the bottom-line.

Shareholder Returns

OPKUS HealthcareUS Market

Return vs Industry: OPK underperformed the US Healthcare industry which returned 2.4% over the past year.

Return vs Market: OPK underperformed the US Market which returned -18.4% over the past year.

Price Volatility

Is OPK's price volatile compared to industry and market?
OPK volatility
OPK Average Weekly Movement11.4%
Healthcare Industry Average Movement9.5%
Market Average Movement8.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: OPK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: OPK's weekly volatility (11%) has been stable over the past year.

About the Company

19915,767Phil Frost

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company’s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins.

OPKO Health Fundamentals Summary

How do OPKO Health's earnings and revenue compare to its market cap?
OPK fundamental statistics
Market CapUS$1.80b
Earnings (TTM)-US$116.65m
Revenue (TTM)US$1.56b


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OPK income statement (TTM)
Cost of RevenueUS$1.15b
Gross ProfitUS$409.36m
Other ExpensesUS$526.02m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date


Earnings per share (EPS)-0.17
Gross Margin26.26%
Net Profit Margin-7.48%
Debt/Equity Ratio14.2%

How did OPK perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is OPK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OPK?

Other financial metrics that can be useful for relative valuation.

OPK key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.3x
Enterprise Value/EBITDA-62.3x
PEG Ration/a

Price to Sales Ratio vs Peers

How does OPK's PS Ratio compare to its peers?

OPK PS Ratio vs Peers
The above table shows the PS ratio for OPK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average1.6x
AMEH Apollo Medical Holdings
ONEM 1Life Healthcare
ADUS Addus HomeCare
MODV ModivCare

Price-To-Sales vs Peers: OPK is good value based on its Price-To-Sales Ratio (1.2x) compared to the peer average (1.6x).

Price to Earnings Ratio vs Industry

How does OPK's PE Ratio compare vs other companies in the US Healthcare Industry?

Price-To-Sales vs Industry: OPK is good value based on its Price-To-Sales Ratio (1.2x) compared to the US Healthcare industry average (1.4x)

Price to Sales Ratio vs Fair Ratio

What is OPK's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OPK PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.2x
Fair PS Ratio1.1x

Price-To-Sales vs Fair Ratio: OPK is expensive based on its Price-To-Sales Ratio (1.2x) compared to the estimated Fair Price-To-Sales Ratio (1.1x).

Share Price vs Fair Value

What is the Fair Price of OPK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: OPK ($2.64) is trading above our estimate of fair value ($0.01)

Significantly Below Fair Value: OPK is trading above our estimate of fair value.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OPK's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is OPKO Health forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: OPK is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OPK is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OPK is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OPK's revenue (2.5% per year) is forecast to grow slower than the US market (8.4% per year).

High Growth Revenue: OPK's revenue (2.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if OPK's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has OPKO Health performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: OPK is currently unprofitable.

Growing Profit Margin: OPK is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: OPK is unprofitable, but has reduced losses over the past 5 years at a rate of 24.9% per year.

Accelerating Growth: Unable to compare OPK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OPK is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (9.8%).

Return on Equity

High ROE: OPK has a negative Return on Equity (-7.22%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is OPKO Health's financial position?

Financial Health Score


Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: OPK's short term assets ($754.1M) exceed its short term liabilities ($309.2M).

Long Term Liabilities: OPK's short term assets ($754.1M) exceed its long term liabilities ($382.8M).

Debt to Equity History and Analysis

Debt Level: OPK's net debt to equity ratio (7.9%) is considered satisfactory.

Reducing Debt: OPK's debt to equity ratio has increased from 4.4% to 14.2% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OPK has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: OPK has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 11.9% each year.

Discover healthy companies


What is OPKO Health current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate OPK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OPK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OPK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OPK's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as OPK has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Phil Frost (85 yo)





Dr. Phillip Frost, also known as Phil, M.D., Ph D., has been the Chairman, Chief Executive Officer and Director of OPKO Health, Inc. since March 27, 2007. Dr. Frost serves as the Managing Director and Gene...

CEO Compensation Analysis

Compensation vs Market: Phil's total compensation ($USD2.10M) is below average for companies of similar size in the US market ($USD5.47M).

Compensation vs Earnings: Phil's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: OPK's management team is seasoned and experienced (8.3 years average tenure).

Board Members

Experienced Board: OPK's board of directors are seasoned and experienced ( 14.4 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: OPK insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

OPKO Health, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: OPKO Health, Inc.
  • Ticker: OPK
  • Exchange: NasdaqGS
  • Founded: 1991
  • Industry: Health Care Services
  • Sector: Healthcare
  • Implied Market Cap: US$1.800b
  • Shares outstanding: 681.95m
  • Website:

Number of Employees


  • OPKO Health, Inc.
  • 4400 Biscayne Boulevard
  • Miami
  • Florida
  • 33137
  • United States


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/26 00:00
End of Day Share Price2022/06/24 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.